Abatacept
The risk or severity of infection can be increased when Golimumab is combined with Abatacept.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Golimumab.
Anakinra
The risk or severity of adverse effects can be increased when Golimumab is combined with Anakinra.
Advertisement
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Golimumab.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Golimumab is combined with Anthrax immune globulin human.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Golimumab.
Advertisement
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Golimumab is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Golimumab is combined with Bacillus calmette-guerin substrain tice live antigen.
Canakinumab
The risk or severity of infection and neutropenia can be increased when Golimumab is combined with Canakinumab.
Advertisement
Certolizumab Pegol
The risk or severity of infection can be increased when Golimumab is combined with Certolizumab pegol.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Golimumab.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Golimumab.
Fingolimod
Golimumab may increase the immunosuppressive activities of Fingolimod.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Golimumab is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Golimumab is combined with Hepatitis B Vaccine (Recombinant).
Infliximab
Golimumab may increase the immunosuppressive activities of Infliximab.
Infliximab-Abda
Golimumab may increase the immunosuppressive activities of Infliximab.
Infliximab-Dyyb
Golimumab may increase the immunosuppressive activities of Infliximab.
Leflunomide
The risk or severity of adverse effects can be increased when Golimumab is combined with Leflunomide.
Natalizumab
The risk or severity of adverse effects can be increased when Golimumab is combined with Natalizumab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Golimumab.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Golimumab.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Golimumab is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Golimumab is combined with Rabies virus inactivated antigen, A.
Rilonacept
The risk or severity of adverse effects can be increased when Golimumab is combined with Rilonacept.
Rituximab
The risk or severity of adverse effects can be increased when Golimumab is combined with Rituximab.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Golimumab.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Golimumab is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Golimumab is combined with Rubella virus vaccine.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Golimumab is combined with Salmonella typhi ty21a live antigen.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Golimumab.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Golimumab.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Golimumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tocilizumab
Tocilizumab may increase the immunosuppressive activities of Golimumab.
Tofacitinib
The risk or severity of adverse effects can be increased when Golimumab is combined with Tofacitinib.
Trastuzumab
Trastuzumab may increase the neutropenic activities of Golimumab.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Golimumab is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Golimumab is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Golimumab is combined with Varicella Zoster Vaccine (Live/Attenuated).
Vedolizumab
The risk or severity of infection can be increased when Golimumab is combined with Vedolizumab.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Golimumab is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Golimumab is combined with Yellow Fever Vaccine.
